Sight Sciences financials
$9.35+0.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | $40.3M |
| Gross margin | 86.2% | 85.5% | 85.3% | 82.7% | 82.4% |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M |
| Net margin | −49.7% | −64.5% | −68.5% | −120.9% | −128.6% |
| Diluted EPS | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 |
| EBITDA | -$36.6M | -$49.8M | -$56.7M | -$83.2M | -$50.8M |
| Operating cash flow | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M |
| Free cash flow | -$29.9M | -$22.7M | -$48.0M | -$76.9M | -$53.4M |
| Diluted shares | 52.1M | 50.1M | 48.6M | 47.8M | 26.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $40.3M | $39.4M | $33.9M | $33.3M | $32.7M |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M |
| Shareholders' equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology